AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children&apos;s Oncology Group

Sarcoma

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial

J Natl Cancer Inst

Oberoi S, Gao Z, Xue W, Randall RL, Coffin CM, Million L, Wolden S, McCarville MB, Kao SC, Venkatramani R, Spunt SL, Weiss AR

doi: 10.1093/jnci/djag211

Leukemia

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009

J Clin Oncol

Gottschalk H, Möricke A, Conter V, Schrappe M, Starý J, Cario G, Dworzak M, Attarbaschi A, Barbaric D, Locatelli F, Bodmer N, Elitzur S, Silvestri D, Dalla-Pozza L, Bergmann AK, Flotho C, Buldini B, Stanulla M, Izraeli S, Rizzari C, Bourquin JP, Biondi A, Valsecchi MG, Zimmermann M

doi: 10.1200/JCO-25-01357

Breast Cancer

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1

J Clin Oncol

Offersen BV, Alsner J, Høgsbjerg K, Nielsen HM, Maae E, Nielsen MH, Mjaaland I, Maraldo MV, Kirkove C, Lörincz T, Al-Rawi S, Blix ES, Schreiber A, Krause M, Kasti UM, Matthiessen LW, Kronborg C, Tramm T, Jensen MB, Overgaard J, DBCG RT Committee

doi: 10.1200/JCO-25-02705

Sarcoma

Malignant peripheral nerve sheath tumors: a report from children's oncology group study ARST0332

J Natl Cancer Inst

Crane JN, Xue W, Qumseya A, Barkauskas DA, Chau K, Tan SY, Hiniker S, Dasgupta R, Venkatramani R, Spunt SL, Weiss AR, Laetsch TW

doi: 10.1093/jnci/djaf359

Central Nervous System Tumors

Cumulative dose of chemotherapy and survival outcomes in children with average risk medulloblastoma treated on Children's Oncology Group study ACNS0331

Neuro Oncol

Wright E, Billups C, Rush S, Li Y, Janns A, Michalski JM, Salloum R, de Blank P

doi: 10.1093/neuonc/noag064

Genitourinary CancerRadio-Oncology

Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533

J Clin Oncol

Dix DB, Khanna G, Renfro LA, Tfirn IC, Smith EA, Artunduaga M, Eklund MJ, Sandberg JK, Parsons LN, Kalapurakal JA, Ehrlich PF, Aldrink JH, Glick RD, Benedetti DJ, Fernandez CV, Dome JS, Mullen EA, Geller JI, COG Renal Tumor Committee

doi: 10.1200/JCO-25-00532

Breast Cancer

A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial

Ann Oncol

Kim GM, Jung KH, Jeung HC, Lee J, Lee KS, Im SA, Kang SY, Kim SH, Kim HJ, Park KH, Chae YS, Koh SJ, Cho EK, Park KU, Lee SS, Kim JY, Choi IS, Baek SK, Moon YW, Kim SG, Lim ST, Lee KH, Kim HJ, Kim MH, Kim KH, Kim SI, Park S, Park HS, Kim JY, Kim YB, Kim SB, Ahn JH, Jeong JH, Kim JH, Jeong J, Park WC, Sim SH, Lee K, Nam CM, Park S, Paik S, Sohn J, Korean Cancer Study Group (KCSG)

doi: 10.1016/j.annonc.2026.05.703

Leukemia

CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial

Blood

Laszig S, Diederichs A, Salzmann-Manrique E, Schuschel K, Goncalves-Dias J, Issa H, Miladinovic M, Rettinger E, Wehner S, Kreyenberg H, Bremm M, Hünecke S, Kerp H, Waack-Buchholz K, Thol FR, Goemans BF, De Moerloose B, Boztug H, Scheidegger NK, Pawinska-Wasikowska K, Reinhardt D, Klusmann JH

doi: 10.1182/blood.2025030775

Head and Neck Cancer

De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial

Lancet Oncol

Ma D, Price K, Moore E, Patel S, Hinni M, Routman D, Fruth B, Foster N, Van Abel K, Yin L, Neben-Wittich M, Garces Y, McGee L, Lester S, Rwigema JC, Holtzman A, Price D, Janus J, Kasperbauer J, Chintakuntlawar A, Garcia J, Foote R

doi: 10.1016/S1470-2045(25)00324-9

Oncology · Hematology

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group

Related content

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1

Malignant peripheral nerve sheath tumors: a report from children's oncology group study ARST0332

Cumulative dose of chemotherapy and survival outcomes in children with average risk medulloblastoma treated on Children's Oncology Group study ACNS0331

Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533

A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial

CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial

De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial